What development does the TB vaccine MTBVAC get as per CDSCO's approval
TB vaccine MTBVAC gets CDSCO nod for phase II trials
- TB vaccine MTBVAC has received approval from the Central Drugs Standard Control Organization (CDSCO) for conducting Phase II clinical trials.
- The Phase II trials will further evaluate the safety and efficacy of the MTBVAC vaccine in preventing tuberculosis.
- MTBVAC is a live attenuated vaccine that aims to provide improved protection against tuberculosis compared to the existing Bacillus Calmette-Guérin (BCG) vaccine.
- The approval from CDSCO signifies that the vaccine has shown promising results in preclinical studies and initial clinical trials.
- Phase II trials will involve testing the vaccine on a larger group of participants to assess its effectiveness and potential side effects.
Answered
a year ago